Background: Maprotiline is a tricyclic antidepressant (sometimes classifi ed as a tetracyclic antidepressant), which is predominantly a norepinephrine/noradrenaline reuptake inhibitor, commonly prescribed for depression. Aim: To present a female patient with depressive episode and occurrence of hyponatremia during the maprotiline treatment. Case Report: A 62-year-old female was diagnosed with depressive episode four years ago. She was treated ambulatory with maprotiline 50mg/day and bromazepam 6mg/ day, from local psychiatrist. The patients also used enalapril 2x10 mg/day, metoprolol 2x50 mg/day, nifedipine 5 mg/day and simvastatin 20 mg/day for treating hypertension and dyslipidemia. After about 12 months of maprotiline use she was hospitalized at the Endocrinology unit of a local hospital due to appearance of confusion, unstable walking, cramps, as well as an increase in blood pressure. Then diagnosed hyponatremia (serum sodium level-112 mmol/L), corrected (137 mmol/L) by using parenteral therapy. The patient continued to use maprotiline without consultation with her psychiatrist. After one year, the patient was hospitalized at the Endocrinology unit of tertiary level due to detailed re-examination because of recurrent hyponatramia (117 mmol/L), corrected (136 mmol/L) by ambulatory use of parenteral therapy at a local hospital. Water test load was used and the Syndrome of inappropriate antidiuretic hormone secretion was diagnosed. Insulin Tolerance Test showed preserved the integrity of the hypothalamic-pituitary-adrenal axis. Antidepressant mirtazapine (15 mg/ day) was introduced due to recurrence of depression. Gradual reduction of depressive symptoms was observed to mirtazapine. Antihypertensive therapy, restriction of fl uid intake and dietary regimen were still applied. Serum sodium concentrations were in the normal ranges over the past 18 months. Conclusion: Serum sodium level should be measured before and during the therapy with any class of antidepressants, especially in those patients with increased risk of the hyponatremia occurrence.
INTRODUCTION
Hyponatremia is an electrolyte abnormality which is clinically defi ned as serum sodium concentration of <135 mEq/L. Th is electrolyte disorder may be complication in the following diseases: heart failure, cirrhosis, adrenocortical insuffi ciency, diabetes mellitus or hyperglycemia, persistent diarrhea and/or vomiting, renal disorders, hypothyroidism, lower body weight, chronic obstructive pulmonary disease (COPD) and acquired immune defi ciency syndrome (AIDS) [1] .
Hyponatremia may occur as a side eff ect of a large number of diff erent drugs, including nearly all psychotropics. Psychotropic drugs may cause hyponatremia by increasing hypothalamic production of antidiuretic hormone (ADH) [antidepressants (ADs) (Tricyclic ADs, Selective serotonin reuptake inhibitors (SSRIs), Monoamine oxidase inhibitors (MAOIs), antipsychotics (phenotiazines, butyrophenones), antiepileptic drugs (oxcarbazepine, sodium valproate)], potentiating of ADH eff ect (antiepileptic drug lamotrigine), resetting osmostat [ADs (Serotonergic and Noradrenergic Reuptake Inhibitors (SNRIs) (venlafaxine, duloxetine), Dopamine Reuptake Inhibitors (DRIs) (bupropion)] or through all of the above mentioned mechanisms (antiepileptic drug carbamazepine), although the exact mechanisms remain unclear.
ADs are most strongly associated with hyponatremia from all psychotropics. According to the reference literature, the risk of hyponatremia is considerably greater with SSRIs and SNRIs in relation to other classes of ADs [1, 2, 3] .
Non-psychotropic drugs that can induce hyponatremia are thiazides diuretics, angiotensin-converting enzyme (ACE) inhibitors, antineoplastic agents, proton pump inhibitors (PPIs), non-steroidal antiimfl ammatory drugs (NSAIDs), antidiabetic drugs, sulphonylureas, analgesics, and exogenous forms of ADH (vasopressin, desmopressin) [4] .
Hyponatremia caused by the use of ADs usually occurs within 2 weeks of starting therapy [4] , but sometimes it may take many months [5] . Risk factors for hyponatremia associated with administration of antidepressants include older age, female gender, somatic comorbid conditions and concomitant therapy. Early symptoms of hyponatremia are nausea, vomiting, anorexia, disorientation, headache, fatigue, weakness, and irritability, lethargy, confusion, and muscle cramps. Clinical severity of hyponatremia depends on the absolute level of serum sodium concentration as well as the abruptness of onset [6] .
CASE REPORT
62 years old female patient, pensioner, living with husband, two children; right-handed. Th e patient had never been a smoker, nor consumed alcohol. She started fi rst time psychiatric outpatient treatment four years ago, because of development of depressive episode of moderate severity. It was preceded by the illness and death of her grandchildren. Th e patient was receiving TCA maprotiline 2x25 mg/ day and bromazepam 2x3 mg/day with regular check-ups with a local psychiatrist in the Health center. Due to cardiologist-diagnosed hypertension and Type 2a dyslipidemia she used enalapril 2x10 mg/day (optionally, with an increase in blood pressure 2x20 mg/day), metoprolol 2x50 mg/day, nifedipine 5 mg/day, simvastatin 20 mg/day, as well as diclofenac (on demand, with the pain) and bromazepam 3 mg/day, on demand. She had no previous history of any endocrine diseases.
Aft er a year of depression treatment with maprotiline and improving mood, there was a deterioration of general condition and appearance of confusion, unstable walking, cramps, along with an increase in blood pressure. At a local hospital was diagnosed hyponatremia (serum sodium concentration-112 mmol/L). Except elevated blood level of cholesterol, the other biochemical and hematological parameters as well as thyroid hormones were within normal ranges. Serum osmolarity was 244 mOsm/kg. Twenty-four hour urinary potassium was 75.3 mmol/L and 24h urinary sodium was 74.7 mmol/L. Computed tomography (CT) brain scan and radiological tests of other systems (X-ray of the heart and lungs and abdominal ultrasound) showed no pathological changes. Serum sodium level was normalized (137 mmol/L) by infusion of saline solution 0.9% and concentrated 10% saline solution and general condition of the patient improved. Except restriction of fl uid intake, enalapril 2x10 mg/day, amlodipine 5 mg/ day and hydrochlorothiazide 12.5 mg every 7 days were prescribed. Aft er discharge from the Endocrinology Department, the patient conwww.hophonline.org tinued to take Maprotiline 2x25 mg/day and Bromazepam 3-6 mg/day, without consultation with her psychiatrist.
One year aft er the previous hospitalization, the patient was admitted to the Institute of Endocrinology of the tertiary level due to detailed re-examination, because of recurrent hyponatremia (117 mmol/l) which was corrected (144 mmol/l) with infusion therapy, conducted in Policlinic of a local hospital. Blood level of glucose, thyroid-stimulating hormone (TSH), free thyroxine (fT4), luteinizing hormone (LH), estradiol, prolactin were in the normal ranges.
Low dose adrenocorticotropic hormone (ACTH) test was normal, but the initial blood cortisol level was low as well as the base value of ACTH. Due to the low probability of hypocorticism, the Insulin Tolerance Test (ITT) [the gold standard for assessing the integrity of the hypothalamic-pituitary-adrenal (HPA) axis] was performed and its values were within normal limits (cortisol -575.4 mmol/L, growth hormone -6.7 mmol/L and prolactine -485.2mmol/L). Serum osmolality was 296 mmol/L and urine osmolality was 215 mmol/L, during water restriction. Magnetic resonance imaging (MRI) of sellar region of pituitary gland showed no pathological changes.
Water test load (WTL) confi rmed the Syndrome of inappropriate antidiuretic hormone secretion (SIADH).
Imaging tests showed no pathological pro-
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cesses that could be the cause of SIADH, and a multi-slice computed tomography (MCTH) of lungs was performed, which showed no pathological changes. Bisoprolol 5mg/day for hypertension was prescribed along with restriction of fl uid intake as well as dietary regimen. She also used bromazepam 3 mg/day and ginkgo biloba (prescribed from otologist for hearing disorder). Aft er discharge, the patient did not use antidepressants, was not heard from a psychiatrist and the mood was getting worse. She was shortly treated in Toxicology unit for taking bromazepam in excessive doses, "to treat insomnia". Th e patient started outpatient's psychiatric treatment at Psychiatric Department of tertiary level due to recurrent depressive episode of moderate severity, which was manifested by depressed mood, tearfulness, anxiety, lack of energy, occasional motor excitation, apathy, social restriction, and decrease in appetite, diffi culty falling and staying asleep. Th e score of self-report Th e Beck Depression Inventory (BDI) [7] was 21 .
Th e investigations that were conducted in the Institute for Endocrinology were excluded endocrine and other somatic causes of hyponatremia. Because her hyponatremia resolved aft er discontinuation of maprotiline therapy, maprotiline was thought to cause the patient's SIADH in this case. We administered Th e Adverse Drug Reaction (ADR) Probability Scale [8] . Th is scale was developed in 1991. by Naranjo and others in order to standardize . Th e score of 9 or higher considered that the reaction is defi nite, probable if 5 to 8, possible if 1 to 4, and doubtful if 0 or less. According to the criteria of the Naranjo Adverse Drug Reaction Probability Scale, the likelihood of maprotiline use causing hyponatremia in this case was "probable" (total score=8) (Table1.). Th e novel antidepressant mirtazapine (15 mg at bad time and aft er 7 days, 30 mg/day), with a dual mode of action (alpha 2 antagonist; enhances the release of norepinephrine and 5-HT1A-mediated serotonergic transmission) (noradrenaline and specifi c serotonergic antidepressants) (NaSSA) was implemented because of its low risk of hyponatremia. Before administration of mirtazapine, serum sodium level was 137 mmol/L. In addition to mirtazapine, the patient has used the fi rst few months bromazepam. Based on selfreporting and family members reporting, the patients adhered to the prescribed pharmacological and non-pharmacological treatment.
Aft er the administration of mirtazapine, in a patient there was a gradual reduction of depressive symptoms and the patient began to perform her daily activities. Th e BDI [7] score was 8. Th e patient is regularly controlled by the cardiologist, blood pressure is normalized (120/80 mmHg), and the current therapy is bisoprolol 2.5 mg/day, enalapril 10 mg/day (with an increase in blood pressure) and simvastatin 20 mg/day. Blood sodium levels were within normal limits over the past 18 months (the most recent value-141 mmol/l).
Given that weight gain is one of the most common side eff ects of mirtazapine, we have followed this parameter in particular. Body mass index (BMI) was 26.5 kg/m2 (body height=1.55 m, body weight=65 kg) before the initiation of mirtazapine treatment. Body weight of the patient wasn't considerably changed during the mirtazapine treatment.
DISCUSSION
A case report of hyponatremia due to maprotiline treatment in patient with a diagnosis of depressive episode has clinical signifi cance, because hyponatremia is a common and potentially dangerous side eff ect of the use of psychotropic drugs [2, 9, 10] . Th e fi ndings of www.hophonline.org previous studies have shown that the highest incidence of this metabolic disorders is in the use of serotonergic ADs [11, 12] . However, a case description of our patient draws attention to the possibility of development of hyponatremia associated with other classes of ADs that are considered not to have a high risk of this side eff ect.
As we showed in our patient's report, hyponatremia may occur during the use of tricyclic antidepressant (TCA) maprotiline [which is sometimes classifi ed as a tetracyclic antidepressant (TeTCA)] [13] . We conducted a detailed clinical, laboratory and other complementary tests [14, 15] , aft er which we excluded endocrine and other somatic diseases as possible causes of hyponatremia in our patients. AD maprotiline proved to be probable cause of this electrolyte imbalance. Aft er discontinuation of the maprotiline therapy, the serum sodium levels were within normal ranges (131-137 mmol/L). According to the criteria of the Naranjo Adverse Drug Reaction Probability Scale, the likelihood of maprotiline use causing hyponatremia in this case was "probable" (score=8). Th is category includes that the reaction a) followed a reasonable temporal sequence aft er a drug, b) followed a recognized response to the suspected drug, c) was confi rmed by withdrawal but not by exposure to the drug, and d) could not be reasonably explained by the known characteristics of the patient's clinical state [8] .
Th e association between the use of ADs and the changes of serum sodium concentration was fi rst described precisely during the application of TCA -amitriptyline, 1974 [16] . And other research fi ndings [17] suggested a considerable association between TCA and the occurrence of hyponatremia. Th e results of some recent studies [18] showed a lower incidence of hyponatremia in the application of TCAs (0.01% -0.33%) in comparison with previous studies (16.7%) [19, 20] , that can be explained by diff erent methodological approaches (active monitoring, higher hyponatremia threshold).
Th e pathogenesis of hyponatremia in the use of TCAs is not clearly understood. Th e patient who was represented, diagnosed with the Syndrome of inappropriate antidiuretic hormone secretion (SIADH) [14, 15] , aft er en-docrine examination. Th is syndrome is usually considered as a cause of hyponatremia induced by ADs. Th us, Mannesse et al. [21] were observed in 50% of the sample recorded SIADH, and with 25% of "possible SIADH". In patients with SIADH, more than half were "most likely" caused by the use of AD, in a third "possible", while in one patient "suspected".
Certain studies have shown that serotonergic mechanisms are involved in regulating the secretion of ADH [22, 23] , while other studies did not confi rm it [24] . Th e animal studies have shown that both neurotransmitters, noraderenalin (NA) and serotonin (5-hydroxy tryptamine) (5-HT) may increase the secretion of ADH by stimulatiing alphaadrenergic and serotonergic receptors [25] . Namely, in the study of Klein [26] has been shown that NA increases the excretion of sodium. It is known that both neurotransmiterrs, NA and 5-HT are involved in the control of secretion of arginine -vasopressin (AVP) [27] . Koelkebeck et al. [28] have pointed to the role of the NA in the development of hyponatremia in a case report of hyponatremia induced by reboxetine (noradrenergic reuptake inhibitor) (NRI). Th ese fi ndings may help in considering the mechanisms of hyponatremia with the administration of the drug, which is used by our patients, maprotiline, bearing in mind its pharmacological profi le (enhances the NA level in the synaptic cleft , through the strong inhibition of its reuptake in the level of presynaptic neuron). Further research is necessary to elucidate the neurobiological mechanisms of occurrence of this undesired eff ect of AD therapy.
Hyponatremia in our patient was diagnosed aft er 12 months of the maprotiline treatment. According to several studies, TCA have attenuated risk profi le for the development of hyponatremia in relation to other classes of ADs. So, later diagnosis of hyponatremia may be associated with a modest reduction in serum sodium level. Early symptoms of this disorder (fatigue, lethargy, weight loss) are nonspecifi c and can mimic the symptoms of psychiatric disorders. According to the literature, the time of occurrence of hyponatremia caused by the use of ADs varies greatly, and the results of the study has shown that this side eff ect of the drug may occur from one day to several months aft er starting therapy [29] . Th is information is important to bear in mind because of the necessity to increase awareness of physicians for this complication of AD therapy, and because of the possibility of its misdiagnosis. It is therefore recommended routine analyzed the serum sodium concentration in the fi rst 2 weeks of therapy in patients with risk factors for development of this electrolytic disturbance as well as in those with lower serum sodium level at the beginning of the treatment. Th is is important, because the delayed recognition and treatment of hyponatremia can lead to irreversible neurological damage and death [30] .
In our patient, there were several risk factors for the occurrence of this electrolyte disturbance: older age (60 yrs.), female sex and the use of concomitant antihypertensive therapy (ACE inhibitor enalapril) [4] .
Th e results of numerous studies have shown that older patients (≥65 years) had more than six fold increased risk for hyponatraemia than younger patients [2] . Bowman et al. [20] indicated that in approximately 25% of elderly patients on the treatment of ADs have occurred hyponatremia. According to Mannesse et al. [21] , in the majority of patients older than 60 years, hyponatremia was caused by the use of TCAs (11.5%), followed by SSRIs (10.2%), venlafaxine (SNRIs) (8.6%) and mirtazapine (NaSSA) (5.6%). Th e reduction in renal blood fl ow, glomerular fi ltration rate and renal tubular damage concentration makes the elderly prone to the occurrence of hyponatremia. Aging also leads to changes in water balance due to changes in stimulating the release of vasopressin and changes in renal response to vasopressin [21] . Th ese data are important because SSRIs are oft en used in the elderly because they have a more favorable adverse eff ects , profi le in relation to TCAs. However, there are studies which show that the occurrence of hyponatremia is not associated with age [21] .
Another drug that the patient used to control hypertension, enalapril (in cotherapy with other antihypertensive agents), that, according to data from the literature, carries a risk for hyponatremia has continued to use even aft er maprotiline off , but there was no electrolyte imbalance. Th e results of Kirby et al. study [31] also showed that concomitant use of non-psychotropic drugs, such as ACE inhibitor in the treatment of arterial hypertension increases the risk of hyponatremia. Hypertension (and other somatic diseases, common in the elderly) [32] may impair the severity of hyponatremia or mask its beginning [33] .
Most studies show that women have greater risk for developing hyponatremia induced by AD therapy. Sex diff erences in occurrence of hyponatremia caused by AD were primarily associated with hormonal activity. Th us, estrogen (but not progesterone) stimulates the secretion of AVP [34] , and women may have a higher sensitivity on ADH with an increase in the expression of vasopressin renal receptors [35] . However, there are studies, whose results have not shown the infl uence of sex on the incidence of hyponatremia with the use of AD therapy [2, 21] .
To continue treatment with mirtazapine [36] , we decided because of demonstrated lower incidence of hyponatremia during administration of this drug [24] . Th e research fi ndings suggested that mirtazapine may be an alternative in the treatment of patients with increased risk of hyponatremia. Th us, the German multicenter drug surveillance program AMSP in psychiatric patients has not found a single case of the occurrence of hyponatremia induced by mirtazapine on a sample of 28172 patients [37] . Th e fi ndings of retrospective study by Jung et al. [38] showed that none of the 76 patients on mirtazapine have developed hyponatremia compared to 8% of patients on SSRIs and 4% of patients on venlafaxine. During the implementation of mirtazapine, in our patient there was an improvement in mood and reduction of anxiety, irritability, and insomnia.
We continue to implement restrictions on fl uid intake, dietary diet and regular check-ups with an endocrinologist and a cardiologist with regular monitoring of serum sodium, and other hematological and biochemical parameters.
CONCLUSION
Considering these facts, it can be concluded that in patients with diff erent risk factors for developing hyponatremia, should determine serum sodium concentration, before and during the application of antidepressant therapy, because many patients may have undiscovered hyponatremia, which can be exacerbated by prescribing antidepressant.
In patients with the appearance of hyponatremia, it is necessary to carry out a detailed endocrine examination, in order to www.hophonline.org exclude other, somatic causes of this electrolyte disturbance. Th e restriction of fl uid intake, along with discontinuation of antidepressant is the fi rst strategies in the treatment. Better awareness and knowledge of risk factors associated with other classes of antidepressants for the development of hyponatremia can help clinicians in the choice of the drug, thus allowing safe treatment for patients at risk, particularly patients with a history of SIADH or those who are showing the fi rst signs of hyponatremia during the current application of AD. www.hophonline.org
